Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York

Rhea-AI Summary

Verrica Pharmaceuticals (Nasdaq: VRCA), a dermatology therapeutics company, announced its upcoming participation in the Citizens Life Sciences Conference in New York City. The company's President and CEO, Jayson Rieger, PhD, MBA, will deliver a presentation at the event.

The presentation is scheduled for Wednesday, May 7, 2025, at 3:00 pm ET and will take place at the New York Hilton Midtown. Interested parties can access a live webcast through the provided link or via the Investors/Presentations & Events section on Verrica's website. The presentation recording will remain available for 90 days after the event.

Verrica specializes in developing medications for skin diseases that require medical interventions, positioning itself as a key player in the dermatology therapeutics sector.

WEST CHESTER, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Citizens Life Sciences Conference in New York City.

Citizens Life Sciences Conference, May 7-8, 2025
Event details:
Date: Wednesday, May 7, 2025
Time: 3:00 pm ET
Location: New York Hilton Midtown, New York

Participants may access a live webcast of the event by clicking the link here.

The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com. A replay of the webcast will be posted shortly after the presentation and will be available for 90 days following the event.

About Verrica Pharmaceuticals Inc. 
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s product YCANTH^® (VP-102) (cantharidin), is the first and only commercially available treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH^® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (formerly LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com.

FOR MORE INFORMATION, PLEASE CONTACT:
Investors:

John J Kirby 
Interim Chief Financial Officer 
jkirby@verrica.com

Kevin Gardner 
LifeSci Advisors 
kgardner@lifesciadvisors.com

FAQ

When is Verrica Pharmaceuticals (VRCA) presenting at the Citizens Life Sciences Conference 2025?

Verrica Pharmaceuticals (VRCA) will present at the Citizens Life Sciences Conference on Wednesday, May 7, 2025, at 3:00 pm ET. The presentation will take place at the New York Hilton Midtown.

How can investors watch Verrica Pharmaceuticals' (VRCA) presentation at the Citizens Life Sciences Conference?

Investors can access a live webcast through a link provided by the company or through the Investors/Presentations & Events section of Verrica's website at www.verrica.com. A replay will be available for 90 days after the event.

Who is representing Verrica Pharmaceuticals (VRCA) at the 2025 Citizens Life Sciences Conference?

Jayson Rieger, PhD, MBA, who serves as President and Chief Executive Officer of Verrica Pharmaceuticals, will represent the company at the conference.

What type of company is Verrica Pharmaceuticals (VRCA)?

Verrica Pharmaceuticals is a dermatology therapeutics company that develops medications for skin diseases requiring medical interventions.

Where can investors find the replay of Verrica Pharmaceuticals' (VRCA) Citizens Conference presentation?

The presentation replay will be available in the Investors/Presentations & Events section of www.verrica.com for 90 days following the May 7, 2025 event.